Chronic Lymphocytic Leukemia Treatment Market Research Report: by Type (Indolent & Aggressive), by Treatment (Chemotherapy, Targeted Drug Therapy, Immunotherapy & Bone Marrow Transplant), by End User (Hospitals & Clinics & Others) - Global Forecast Till 2023

ID: MRFR/Pharma/5435-HCR | February 2021 | Region: Global | 90 pages

Global Chronic Lymphocytic Leukemia (CLL) Treatment Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 7.9 Billion in 2017 and is projected to grow at a CAGR of 19% over the forecast period. Chronic Lymphocytic Leukemia is a type of cancer that affects a specific type of white blood cell known as lymphocyte., The factors such as rising prevalence of leukemia as well as CLL, increasing research & development activities and technological advancements related to the treatment are expected to propel the growth of the market. However, the high cost of treatment and stringent government regulations can hamper the market growth over the forecast period., Segmentation:, The Global Chronic Lymphocytic Leukemia Treatment Market has been segmented into type, treatment and end user. The market, on the basis of type, has been segmented into indolent CLL and aggressive CLL., The market, by treatment, has been segmented into chemotherapy, targeted drug therapy, immunotherapy and bone marrow transplant., The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, research institutes and others., The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic lymphocytic leukemia treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. , The European chronic lymphocytic leukemia treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. , The chronic lymphocytic leukemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic lymphocytic leukemia treatment market in the Middle East & Africa has been segmented into the Middle East and Africa., Key players:, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELGENE CORPORATION, Genmab A/S, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Genzyme Corporation, AbbVie Inc., Gilead, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., TG Therapeutics, Inc., Ziopharm Oncology, Inc. and others are some of the key players in the global chronic lymphocytic leukemia treatment market., Regional Mar

Market Scenario:

The factors such as rising prevalence of leukemia as well as CLL, increasing research & development activities and technological advancements related to the treatment are expected to propel the growth of the market. However, the high cost of treatment and stringent government regulations can hamper the market growth over the forecast period.

Segmentation:

The Global Chronic Lymphocytic Leukemia Treatment Market has been segmented into type, treatment and end user. The market, on the basis of type, has been segmented into indolent CLL and aggressive CLL.

The market, by treatment, has been segmented into chemotherapy, targeted drug therapy, immunotherapy and bone marrow transplant.

The market, by end user, has been segmented into hospitals & clinics, diagnostic laboratories, research institutes and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The chronic lymphocytic leukemia treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European chronic lymphocytic leukemia treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The chronic lymphocytic leukemia treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The chronic lymphocytic leukemia treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, CELGENE CORPORATION, Genmab A/S, Teva Pharmaceutical Industries Ltd., Genentech, Inc., Genzyme Corporation, AbbVie Inc., Gilead, Novartis AG, Johnson & Johnson Services, Inc., AstraZeneca, ONO PHARMACEUTICAL CO., LTD., TG Therapeutics, Inc., Ziopharm Oncology, Inc. and others are some of the key players in the global chronic lymphocytic leukemia treatment market.

Regional Market Summary:

Global Chronic Lymphocytic Leukemia Treatment Market Share (%), by Region, 2017

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports

Geographically, the Americas is anticipated to dominate the global chronic lymphocytic leukemia treatment market owing to rising prevalence of leukemia and presence of major market players. According to a report published by the Leukemia & Lymphoma Society in 2018, every 3 minutes one person in the US is diagnosed with blood cancer (leukemia).

Europe is expected to hold the second largest position in the global chronic lymphocytic leukemia treatment market. The market growth in this region is attributed to rising research and development activities in the field of leukemia. The chronic lymphocytic leukemia treatment market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the rising prevalence of leukemia and growing demand for treatment of the disease. According to a report published by the World Health Organization in 2017, 8,904 leukemia deaths were reported in Japan.

The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.

Global Chronic Lymphocytic Leukemia Treatment Market, by Type:

Indolent CLL

Aggressive CLL

Global Chronic Lymphocytic Leukemia Treatment Market, by Treatment:

Chemotherapy

Targeted Drug Therapy

Immunotherapy

Bone Marrow Transplant

Global Chronic Lymphocytic Leukemia Treatment Market, by End User:

Hospitals and Clinics

Diagnostic Laboratories

Research Institutes

Others

Global Chronic Lymphocytic Leukemia Treatment Market, by Region:

Americas

North America

Canada

South America

Europe

Western Europe

Germany

France

Italy

Spain

Rest of Western Europe

Eastern Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

The Middle East & Africa

Middle East

Africa

Global Chronic Lymphocytic Leukemia Treatment Market, by Key Players:

Hoffmann-La Roche Ltd

GlaxoSmithKline plc

CELGENE CORPORATION

Genmab A/S

Teva Pharmaceutical Industries Ltd.

Genentech, Inc.

Genzyme Corporation

AbbVie Inc.

Gilead

Novartis AG

Johnson & Johnson Services, Inc.

AstraZeneca

ONO PHARMACEUTICAL CO., LTD.

TG Therapeutics, Inc.

Ziopharm Oncology, Inc.

Intended Audience:

Pharmaceutical Companies

Research Laboratories

Oncology Laboratories

Healthcare Organizations

Frequently Asked Questions (FAQ) :

What is the current valuation of the Chronic Lymphocytic Leukemia Treatment Market?

Chronic Lymphocytic Leukemia Treatment Market had a valuation of USD 7.9 billion in 2017.

What would be the CAGR of the Chronic Lymphocytic Leukemia Treatment Market during the forecast period of 2018 to 2023?

Chronic Lymphocytic Leukemia Treatment Market would record a CAGR of 19% during the forecast period of 2018 to 2023.

What are the end users involved in the Chronic Lymphocytic Leukemia Treatment Market?

Chronic Lymphocytic Leukemia Treatment Market would have end users like research institutes, diagnostic laboratories, hospitals & clinics, and others.

What are the treatment segments discussed in the Chronic Lymphocytic Leukemia Treatment Market?

Chronic Lymphocytic Leukemia Treatment Market has been discussed on the basis of treatments like targeted drug therapy, chemotherapy, immunotherapy, and bone marrow transplant.

Which region is leading the global Chronic Lymphocytic Leukemia Treatment Market?

Americas are leading the Chronic Lymphocytic Leukemia Treatment Market.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Equipment Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Chronic Lymphocytic Leukemia Treatment (CLL) Market, by Type

6.1 Introduction

6.2 Indolent CLL